Tag: trending OOS data

Top 10 Regulatory Questions About OOS Investigations in Stability Testing

Posted on By

Out-of-Specification (OOS) results in pharmaceutical stability studies can trigger complex investigations, delayed batch releases, and even regulatory actions. Health authorities like the USFDA, EMA, and CDSCO expect a structured, compliant, and data-driven response. This article addresses the top 10 questions raised by regulators during inspections and how pharma companies can prepare effectively. 📌 1. Do…

Read More “Top 10 Regulatory Questions About OOS Investigations in Stability Testing” »

Out-of-Specification (OOS) Stability Studies, Regulatory Guidelines

Documenting Excursions and OOS Events in Reports

Posted on By

Excursions and out-of-specification (OOS) results are inevitable in long-term pharmaceutical stability studies. Whether due to chamber malfunction, unexpected assay drift, or analytical errors, these events must be thoroughly documented in the stability report. Regulatory agencies such as the USFDA, CDSCO, and EMA require a standardized approach to documenting, investigating, and concluding on such deviations. This…

Read More “Documenting Excursions and OOS Events in Reports” »

Protocols and Reports, Stability Testing Report Generation and Documentation